Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Captopril in heart failure.

E Kékes1

  • 1Second Medical Department (Cardiology), Postgraduate Medical School, Budapest, Hungary.

Acta Physiologica Hungarica
|January 1, 1988
PubMed
Summary

Captopril effectively treats heart failure by inhibiting angiotensin-converting enzyme (ACE). This action normalizes renin, angiotensin II, and aldosterone levels, improving symptoms and fluid balance.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Cardiovascular risk factors in essential hypertension].

Orvosi hetilap·2001
Same author

[Current status and possibilities of distant education in medicine].

Orvosi hetilap·2000
Same author

[Captopril in the treatment of heart failure].

Acta pharmaceutica Hungarica·1997
Same author

Third generation electronic medical record knowledge based perspectives.

Medinfo. MEDINFO·1995
Same author

Testing the knowledge of postgraduate trainees in medicine: a multimedia software package.

Medinfo. MEDINFO·1995
Same author

[Antianginal effect of transdermal isosorbide dinitrate (multicenter study)].

Orvosi hetilap·1994

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Heart failure is associated with elevated renin, angiotensin II, and aldosterone.
  • These hormonal changes contribute to pathological abnormalities in heart failure.

Purpose of the Study:

  • To investigate the effects of captopril, an ACE inhibitor, on heart failure markers.
  • To evaluate the clinical benefits of ACE inhibition in heart failure patients.

Main Methods:

  • Administration of captopril to patients with heart failure.
  • Monitoring of renin, angiotensin II, and aldosterone plasma levels.
  • Assessment of clinical symptoms and fluid/electrolyte balance.

Main Results:

  • Captopril successfully inhibited ACE.
  • Plasma levels of renin, angiotensin II, and aldosterone were normalized.
  • Significant improvement in heart failure symptoms was observed.
  • Increased excretion of sodium and water, alongside elevated serum potassium levels, was noted.

Conclusions:

  • ACE inhibition with captopril is a viable therapeutic strategy for heart failure.
  • Captopril demonstrates favorable clinical effects, including symptom improvement and favorable electrolyte shifts.

Related Experiment Videos